CreoSG Co.,Ltd. (KOSDAQ:040350)
7,150.00
-650.00 (-8.33%)
At close: Jul 20, 2026
CreoSG Revenue
CreoSG had revenue of 2.63B KRW in the quarter ending March 31, 2026, with 30.49% growth. This brings the company's revenue in the last twelve months to 11.48B, up 38.57% year-over-year. In the year 2025, CreoSG had annual revenue of 10.86B with 33.15% growth.
Revenue (ttm)
11.48B
Revenue Growth
+38.57%
P/S Ratio
12.14
Revenue / Employee
279.90M
Employees
41
Market Cap
139.28B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.86B | 2.70B | 33.15% |
| Dec 31, 2024 | 8.16B | -1.60B | -16.39% |
| Dec 31, 2023 | 9.76B | -24.95M | -0.26% |
| Dec 31, 2022 | 9.78B | 1.15B | 13.27% |
| Dec 31, 2021 | 8.64B | -1.18B | -12.02% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Dongyang E&P | 555.88B |
| Hwashin Precision Engineering | 411.93B |
| Daihan Pharmaceutical | 211.44B |
| GC MediAI | 202.23B |
| Cheil Electric | 197.02B |
| MegaStudy | 126.04B |
| SM Culture & Contents | 104.26B |
| Orbitech | 66.56B |